{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:19:56Z","timestamp":1793668796202,"version":"4.5.1"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Recent studies indicate that gut microbiota disorders potentially contribute to the pathogenesis of irritable bowel syndrome (IBS), which can be partly reflected by fecal short-chain fatty acids (SCFAs) generated from gut microbiota. Previous studies on SCFA alterations in patients with IBS have yielded conflicting results. No prior systematic review has been conducted on the alterations in fecal SCFAs in IBS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>We performed a meta-analysis to explore and clarify alterations in fecal SCFAs in IBS patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Case-control studies, randomized controlled trials (RCTs), and self-controlled studies were identified through electronic database searches. The standardized mean difference (SMD) with 95% confidence interval (CI) in fecal SCFA levels between different groups was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The proportion of fecal propionate in patients with IBS was significantly higher than in healthy controls (HCs) (SMD\u200a=\u200a0.44, 95% CI\u200a=\u200a0.12, 0.76). A subgroup analysis showed that the concentration of fecal propionate (SMD\u200a=\u200a\u22120.91, 95% CI\u200a=\u200a\u22121.41, \u22120.41) and butyrate (SMD\u200a=\u200a\u22120.53, 95% CI\u200a=\u200a\u22121.01, \u22120.04) in patients with constipation-predominant IBS (IBS-C) was significantly lower than that in HCs, and the concentration of fecal butyrate in patients with diarrhea-predominant IBS (IBS-D) was higher than that in HCs (SMD\u200a=\u200a0.34, 95% CI\u200a=\u200a0.00, 0.67). Finally, we found that restricted diets correlated with fecal butyrate reduction in IBS (SMD\u200a=\u200a\u22120.26, 95% CI\u200a=\u200a\u22120.51, \u22120.01).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>In terms of fecal SCFAs, there were differences between patients with IBS and HCs. In IBS-C patients, propionate and butyrate were reduced, whereas butyrate was increased in IBS-D patients in comparison to HCs. Propionate and butyrate could be used as biomarkers for IBS diagnosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000014513","type":"journal-article","created":{"date-parts":[[2019,2,14]],"date-time":"2019-02-14T00:59:03Z","timestamp":1550105943000},"page":"e14513","source":"Crossref","is-referenced-by-count":131,"title":["Alterations in fecal short-chain fatty acids in patients with irritable bowel syndrome"],"prefix":"10.1097","volume":"98","author":[{"given":"Qinghua","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/gut.52.11.1616","article-title":"Cluster analysis of symptoms and health seeking behaviour differentiates subgroups of patients with severe irritable bowel syndrome","volume":"52","author":"Guthrie","year":"2003","journal-title":"Gut"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1053\/j.gastro.2006.03.008","article-title":"The functional gastrointestinal disorders and the Rome III process","volume":"130","author":"Drossman","year":"2006","journal-title":"Gastroenterology"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"936960","DOI":"10.1155\/2012\/936960","article-title":"Benefits from long-term treatment in irritable bowel syndrome","volume":"2012","author":"Evangelista","year":"2012","journal-title":"Gastroenterol Res Pract"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1111\/j.1572-0241.2006.00789.x","article-title":"Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation","volume":"101","author":"M\u00fcller-Lissner","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2036.2004.02294.x","article-title":"Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation","volume":"21","author":"M\u00fcller-Lissner","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.3748\/wjg.v20.i10.2482","article-title":"Irritable bowel syndrome and small intestinal bacterial overgrowth: meaningful association or unnecessary hype","volume":"20","author":"Ghoshal","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"14105","DOI":"10.3748\/wjg.v20.i39.14105","article-title":"Irritable bowel syndrome: a microbiome-gut-brain axis disorder?","volume":"20","author":"Kennedy","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1136\/gutjnl-2011-301501","article-title":"An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota","volume":"61","author":"Jeffery","year":"2012","journal-title":"Gut"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800100-4.00003-9","article-title":"The role of short-chain fatty acids in health and disease","volume":"121","author":"Tan","year":"2014","journal-title":"Adv Immunol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"C979","DOI":"10.1152\/ajpcell.00228.2014","article-title":"From microbe to man: the role of microbial short chain fatty acid metabolites in host cell biology","volume":"307","author":"Natarajan","year":"2014","journal-title":"Am J Physiol Cell Physiol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"e58204","DOI":"10.1371\/journal.pone.0058204","article-title":"An investigation of fecal volatile organic metabolites in irritable bowel syndrome","volume":"8","author":"Ahmed","year":"2013","journal-title":"PLoS One"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/518S3a","article-title":"Gut microbiome: the peacekeepers","volume":"518","author":"Velasquez-Manoff","year":"2015","journal-title":"Nature"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3390\/nu3100858","article-title":"Regulation of inflammation by short chain fatty acids","volume":"3","author":"Vinolo","year":"2011","journal-title":"Nutrients"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/01.NAJ.0000520253.57459.01","article-title":"Irritable bowel syndrome","volume":"117","author":"Weaver","year":"2017","journal-title":"Am J Nurs"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"R16-20230914","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/01.NAJ.0000431911.65473.35","article-title":"Managing irritable bowel syndrome","volume":"113","author":"Anastasi","year":"2013","journal-title":"Am J Nurs"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1111\/1462-2920.14271","article-title":"Fecal Clostridiales distribution and short-chain fatty acids reflect bowel habits in irritable bowel syndrome","volume":"20","author":"Gargari","year":"2018","journal-title":"Environ Microbiol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-016-0446-z","article-title":"Faecal short-chain fatty acids \u2013 a diagnostic biomarker for irritable bowel syndrome?","volume":"16","author":"Farup","year":"2016","journal-title":"BMC Gastroenterol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/ajg.2015.220","article-title":"Altered colonic bacterial fermentation as a potential pathophysiological factor in irritable bowel syndrome","volume":"110","author":"Ringel-Kulka","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"R20-20230914","first-page":"512","article-title":"Altered profiles of intestinal microbiota and organic acids may be the origin of symptoms in irritable bowel syndrome","volume":"22","author":"Tana","year":"2010","journal-title":"Neurogastroenterol Motil"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1136\/gutjnl-2014-307264","article-title":"Diets that differ in their FODMAP content alter the colonic luminal microenvironment","volume":"64","author":"Halmos","year":"2015","journal-title":"Gut"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1440-1746.2012.07291.x","article-title":"Alternative investigations for irritable bowel syndrome","volume":"28","author":"Philpott","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2036.2007.03391.x","article-title":"Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome","volume":"26","author":"Kajander","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/MIB.0b013e31829a91f6","article-title":"Analysis of volatile organic compounds of bacterial origin in chronic gastrointestinal diseases","volume":"19","author":"Walton","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/2050640617736478","article-title":"Effect of Lactobacillus paracasei CNCM I-1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial","volume":"6","author":"Cremon","year":"2018","journal-title":"United European Gastroenterol J"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00005176-199610000-00013","article-title":"Fecal short-chain fatty acids in patients with diarrhea-predominant irritable bowel syndrome: in vitro studies of carbohydrate fermentation","volume":"23","author":"Treem","year":"1996","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1111\/j.1365-2036.2012.05007.x","article-title":"Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome","volume":"35","author":"Chassard","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"65","DOI":"10.2147\/CEG.S11349","article-title":"Intestinal fermentation in patients with self-reported food hypersensitivity: painful, but protective?","volume":"3","author":"Valeur","year":"2010","journal-title":"Clin Exp Gastroenterol"},{"key":"R31-20230914","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2362.1987.tb01234.x","article-title":"Seeking clues for a positive diagnosis of the irritable bowel syndrome","volume":"17","author":"Vernia","year":"1987","journal-title":"Eur J Clin Invest"},{"key":"R32-20230914","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000199085","article-title":"Faecal weight, constituents, colonic motility, and lactose tolerance in the irritable bowel syndrome","volume":"30","author":"Eastwood","year":"1984","journal-title":"Digestion"},{"key":"R33-20230914","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000448280","article-title":"Fecal fermentation in irritable bowel syndrome: influence of dietary restriction of fermentable oligosaccharides, disaccharides, monosaccharides and polyols","volume":"94","author":"Valeur","year":"2016","journal-title":"Digestion"},{"key":"R34-20230914","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1038\/ctg.2016.32","article-title":"Effects of rifaximin on transit, permeability, fecal microbiome, and organic acid excretion in irritable bowel syndrome","volume":"7","author":"Acosta","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"R35-20230914","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1097\/MCG.0000000000000653","article-title":"World Gastroenterology Organisation Global Guidelines Irritable Bowel Syndrome: A Global Perspective Update September 2015","volume":"50","author":"Quigley","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"R36-20230914","doi-asserted-by":"crossref","first-page":"e12969","DOI":"10.1111\/nmo.12969","article-title":"Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microenvironment, and cytokine profiles in patients with irritable bowel syndrome","volume":"29","author":"Hustoft","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"R37-20230914","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.3945\/jn.112.159285","article-title":"Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome","volume":"142","author":"Staudacher","year":"2012","journal-title":"J Nutr"},{"key":"R38-20230914","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/ismej.2012.158","article-title":"Butyrate-producing Clostridium cluster XIVa species specifically colonize mucins in an in vitro gut model","volume":"7","author":"Van den Abbeele","year":"2013","journal-title":"ISME J"},{"key":"R39-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-6968.2009.01514.x","article-title":"Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine","volume":"294","author":"Louis","year":"2009","journal-title":"FEMS Microbiol Lett"},{"key":"R40-20230914","doi-asserted-by":"crossref","first-page":"e00889","DOI":"10.1128\/mBio.00889-14","article-title":"Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data","volume":"5","author":"Vital","year":"2014","journal-title":"mBio"},{"key":"R41-20230914","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.mib.2013.06.003","article-title":"Faecalibacterium prausnitzii and human intestinal health","volume":"16","author":"Miquel","year":"2013","journal-title":"Curr Opin Microbiol"},{"key":"R42-20230914","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.gastro.2016.09.049","article-title":"Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome","volume":"152","author":"Tap","year":"2017","journal-title":"Gastroenterology"},{"key":"R43-20230914","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1574-6968.2006.00171.x","article-title":"Diversity of the Clostridium coccoides group in human fecal microbiota as determined by 16S rRNA gene library","volume":"257","author":"Hayashi","year":"2006","journal-title":"FEMS Microbiol Lett"},{"key":"R44-20230914","doi-asserted-by":"crossref","first-page":"39399","DOI":"10.1038\/srep39399","article-title":"The human intestinal microbiota of constipated-predominant irritable bowel syndrome patients exhibits anti-inflammatory properties","volume":"6","author":"Gobert","year":"2016","journal-title":"Sci Rep"},{"key":"R45-20230914","doi-asserted-by":"crossref","first-page":"R1269","DOI":"10.1152\/ajpregu.00442.2002","article-title":"Short-chain fatty acids stimulate colonic transit via intraluminal 5-HT release in rats","volume":"284","author":"Fukumoto","year":"2003","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"R46-20230914","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3389\/fmicb.2016.00979","article-title":"Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut","volume":"7","author":"Rivi\u00e8re","year":"2016","journal-title":"Front Microbiol"},{"key":"R47-20230914","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/BOR.0000000000000191","article-title":"Influence and effect of the human microbiome in allergy and asthma","volume":"27","author":"Panzer","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"R48-20230914","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/SHK.0b013e3181f6aaf1","article-title":"The mucus layer is critical in protecting against ischemia-reperfusion-mediated gut injury and in the restitution of gut barrier function","volume":"35","author":"Qin","year":"2011","journal-title":"Shock"},{"key":"R49-20230914","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2217\/FMB.15.54","article-title":"Gut permeability, its interaction with gut microflora and effects on metabolic health are mediated by the lymphatics system, liver and bile acid","volume":"10","author":"Tran","year":"2015","journal-title":"Future Microbiol"},{"issue":"(Suppl 2)","key":"R50-20230914","first-page":"251","article-title":"Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions","volume":"59","author":"Tazoe","year":"2008","journal-title":"J Physiol Pharmacol"},{"key":"R51-20230914","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/j.1758-2229.2012.00327.x","article-title":"Structural alterations of faecal and mucosa-associated bacterial communities in irritable bowel syndrome","volume":"4","author":"Durb\u00e1n","year":"2012","journal-title":"Environ Microbiol Rep"},{"key":"R52-20230914","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2982.2012.01891.x","article-title":"Alterations in composition and diversity of the intestinal microbiota in patients with diarrhea-predominant irritable bowel syndrome","volume":"24","author":"Carroll","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"R53-20230914","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fnut.2018.00119","article-title":"Fecal short chain fatty acids and dietary intake in Italian women with restrictive anorexia nervosa: a pilot study","volume":"5","author":"Speranza","year":"2018","journal-title":"Front Nutr"},{"key":"R54-20230914","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.jnutbio.2018.11.003","article-title":"Impact of dietary fiber supplementation on modulating microbiota-host-metabolic axes in obesity","volume":"64","author":"Mayengbam","year":"2018","journal-title":"J Nutr Biochem"},{"key":"R55-20230914","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable bowel syndrome","volume":"376","author":"Ford","year":"2017","journal-title":"N Engl J Med"},{"key":"R56-20230914","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00094-18","article-title":"Butyrate producers as potential next-generation probiotics: safety assessment of the administration of Butyricicoccus pullicaecorum to healthy volunteers","volume":"3","author":"Boesmans","year":"2018","journal-title":"mSystems"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201902150-00064","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T15:25:42Z","timestamp":1694705142000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201902150-00064"}},"subtitle":["A systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":55,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000014513","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2]]}}}